ID-10042227The FDA just approved Vvyanse, also known as lisdexamfetamine dimesylate, a central nervous system stimulant, for the treatment of binge-eating disorder. This is the first drug approved by the FDA to treat adults with recurring bouts of compulsive overeating. Patients with this condition eat when they are not hungry and often eat to the point of being uncomfortably full. Binge-eating disorder may lead to weight gain and to health problems related to obesity Vyvanse was first approved in 2007 as a once daily treatment of ADHD in individuals ages 6 and older. Vyvanse is a Schedule II controlled substance because it has high potential for abuse, with use potentially leading to dependence. The efficacy of Vyvanse in treating binge-eating disorder was shown in two clinical studies that included 724 adults with moderate-to-severe binge-eating disorder. Participants taking Vyvanse experienced a decrease in the number of binge eating days per week and had fewer obsessive-compulsive binge eating behaviors compared to those treated with placebo. Vyvanse is dispensed with a Medication Guide for patients, which includes information about adverse effects. How do you counsel patients about the effects of stimulants or controlled substances?

For additional information click here
Photo courtesy of [Keattikorn]